Clinical Report: Mild metabolic profile may mask MASLD risk
Overview
This study identifies five distinct subgroups of metabolic dysfunction-associated steatotic liver disease (MASLD) with varying genetic profiles and disease trajectories. Notably, a polygenic subgroup with mild metabolic abnormalities presents significant long-term liver risks.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern, particularly due to its complex interplay of genetic, metabolic, and environmental factors. Understanding the heterogeneity of MASLD is crucial for effective risk stratification and management, as it encompasses a spectrum from simple steatosis to severe liver disease.
Data Highlights
Subgroup
Percentage of Patients
Long-term Liver Risk
C1: Cardiometabolic MASLD without obesity
31%
Lower
C2: Male-predominant cardiorenal MASLD
27%
Higher
C3: Female-predominant MASLD with obesity
24%
Higher
C4: Polygenic MASLD
9%
Substantial
C5: Polygenic MASH
10%
Elevated
Key Findings
Five reproducible subgroups of MASLD were identified based on clinical and demographic variables.
The polygenic MASLD subgroup (C4) exhibited mild metabolic abnormalities but significant liver-specific risks.
Patients in C5 had more than double the likelihood of developing metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis compared to C1.
Long-term liver transplantation likelihood was 16% in C4 and 10% in C5 over 10 years.
Subgroups C2 and C3 showed heterogeneous metabolic profiles, while C4 and C5 were more liver-focused.
Clinical Implications
The identification of distinct MASLD subgroups emphasizes the importance of understanding genetic and metabolic risk profiles.
Conclusion
This study highlights the complexity of MASLD and the need for further research to refine subgroup assignments and validate findings across diverse populations.
Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
Nearly 40% of patients initiated thyroid hormone therapy within 2 years of hemithyroidectomy, with higher preoperative thyroid‐stimulating hormone levels and thyroid cancer identifying those at greatest risk.
